
EFFECTIVE CARE OF EXPERIMENTAL DIABETES DEPENDS ON REGULAR MONITORING OF GLUCOSE AND GLYCATED HEMOGLOBIN LEVELS

Sobirova D. R.
Tashkent medical academy

Studying the morphofunctional state of pulmonary vascular endothelium in the alloxan diabetes model as a key aspect in evaluating the impact of diabetes on the pulmonary circulatory system

The study analyzed the morphometric changes in small and medium-diameter pulmonary blood vessels. It was found that alloxan diabetes leads to thickening of pulmonary capillary walls, narrowing of vessel diameters, and endothelial damage. These pathological processes are primarily associated with endothelial dysfunction, cellular degeneration, and the toxic effects of glucose.

The research results revealed that diabetes causes interstitial edema, an increase in collagen deposits, and microcirculatory disruptions in pulmonary blood vessels. These morphometric changes result in hypoxia and disturbances in pulmonary circulation as complications of diabetes. The findings of this study contribute to a better understanding of pathological processes in the pulmonary vascular endothelium in diabetes and aim to develop treatment strategies in this field.

Keywords: Alloxan diabetes, pulmonary blood vessels, morphometry, endothelial dysfunction, microcirculation.

Materials and Methods: The study was conducted on male, outbred white laboratory rats weighing 170–185 g. The animals were kept in standard vivarium conditions with natural feeding and free access to water. An experimental diabetes model was induced using the alloxan preparation (Lachema, Czechoslovakia) administered intraperitoneally at a dose of 130 mg/kg body weight. The animals were fasted for 24 hours to facilitate the development of diabetes. The onset of diabetes was confirmed by measuring blood glucose levels using a Contour Plus glucometer.

Morphometric analysis of lung tissues and blood vessels was conducted on 116 rats at various time points. Micropreparations of lung tissues were obtained from decapitated rats. Tissue components, cellular structures, blood vessel diameters, wall thickness, and affected cells were examined in sections stained with hematoxylin and eosin. A NanoZoomer (REF C13140-21.S/N000198/HAMAMATSU PHOTONICS/431-3196 JAPAN) was used to scan the samples at 200x magnification, and correlations were analyzed using software-based formulas without human intervention.

Study Results:

The table above illustrates the morphometric changes in pulmonary blood vessels observed under the conditions of the alloxan diabetes model. It presents the changes in various parts of the pulmonary vasculature over 30, 60, 90, and 120 days, as well as comparisons with the control group. Below are the detailed findings:

Thickness of Alveolar Capillary Endothelium Layers. The thickness of the endothelial layer in pulmonary capillaries increased with the progression of diabetes. In the control group, the endothelial layer thickness was $9.2 \pm 1.11 \mu\text{m}$. A significant thickening was observed from 30 days, reaching $10.99 \pm 1.15 \mu\text{m}$ by day 120. This thickening is attributed to the toxic effects of glucose on the endothelium and interstitial edema, which contribute to capillary wall thickening.

This study highlights the pathological changes in the pulmonary vascular endothelium associated with diabetes, providing valuable insights for developing therapeutic approaches.

Muscular Layer of Pulmonary Segmental Vessel Walls. The thickness of the muscular layer in pulmonary segmental vessel walls significantly increased with the progression of diabetes. In the control group, this parameter was $28.11 \pm 1.10 \mu\text{m}$, while it reached $32.02 \pm 1.05 \mu\text{m}$ at 30 days and a maximum of $43.04 \pm 1.01 \mu\text{m}$ at 90 days. This thickening is associated with hyperplasia of the muscular layer and an increase in collagen deposits in the vessel wall.

Average Diameter of Primary Branch of Pulmonary Lobule (mm). The diameter of vessels located around primary bronchioles increased under diabetic conditions. In the control group, this parameter was $3.35 \pm 3.07 \text{ mm}$,



while it reached 7.8 ± 2.05 mm by day 120. This change is explained by disruptions in microcirculation and the expansion of vessel walls.

Average Diameter of Secondary Branch of Pulmonary Lobule (mm). The diameter of secondary blood vessels also increased with the progression of diabetes. In the control group, this parameter was 2.2 ± 0.85 mm, rising to 3.1 ± 1.84 mm by day 120. These changes indicate morphological alterations in vessel walls and the toxic effects of glucose on blood vessels.

Average Diameter of Tertiary Branch of Pulmonary Lobule (mm). Changes in the diameter of tertiary distributing vessels were relatively less pronounced. In the control group, this parameter was 1.86 ± 2.01 mm, increasing to 2.2 ± 4.16 mm by day 120. These changes result from the effects of glucose on vascular endothelium and interstitial cells.

Conclusion: The study identified morphometric changes in pulmonary blood vessels under conditions of alloxan-induced diabetes, including thickening of vessel walls, endothelial damage, and the expansion of vessel diameters. These findings indicate the adverse impact of diabetes on the pulmonary circulatory system. Such data are essential for a deeper understanding of pulmonary complications in diabetes and for developing therapeutic approaches aimed at preventing these complications.

References

1. Sobirova, D. R., Azizova, F. X., Ishandjanova, S. X., Otajanova, A. N., & Utepova, N. B. (2021). Study of changes in pulmonary alveolar epithelium and aerogematic barrier in diabetes mellitus.
2. Собирова, Д. Р., Нуралиев, Н. А., & Усманов, Р. Д. (2018). Оценка медико-биологической безопасности генно-модифицированного продукта. *Методические рекомендации*, 19, 38-40.
3. Sobirova, D. R., & Shamansurova, K. S. (2016). Features of influence of the new product obtained by new technologies on animal organism in the experiment. In *The Eleventh European Conference on Biology and Medical Sciences* (pp. 44-46).
4. Собирова, Д. Р., Усманов, Р. Д., Азизова, Ф. Х., Шигакова, Л. А., & Утепова, Н. Б. (2023, June). ҚАНДЛИ ДИАБЕТ КАСАЛЛИГИДА ЎПКАНИНГ МОРФОФУНКЦИОНАЛ КЎРСАТКИЧЛАРИ. In *Conferences* (pp. 40-41).



5. Давлетьянц, Г. Л., Нуритдинова, Н. Б., Зуева, Е. Б., & Усманов, Р. И. (2000). Клиническая и гемодинамическая эффективность небиволола у больных с гипертонической болезнью и сердечной недостаточностью. *Кардиология*, 40(12), 64.
6. Абдуллаев, С. П., Бендингер, М. Н., Юлдашева, Х. Ю., Нуритдинова, Н. Б., & Шукурджанова, С. М. (2010). Особенности лечения артериальной гипертензии у лиц пожилого возраста. *Кардиология Узбекистана. Ташкент*, (2-3), 17.
7. Ярмухамедова, Д. З., Нуритдинова, Н. Б., Шоалимова, З. М., Махмудова, М. С., & Ибрагимов, З. С. (2021). РАСПРОСТРАНЕННОСТЬ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ И ФАКТОРОВ РИСКА У ЛИЦ МОЛОДОГО ВОЗРАСТА. *Наука, техника и образование*, (3 (78)), 60-63.
8. Mahmudova, M. S., Shukurdjanova, S. M., & Nuritdinova, N. B. (2022). Complications of Parkes Weber syndrome.
9. Абдумаликова, Ф. Б., Нуриллаева, Н. М., Нуритдинова, Н. Б., & Шукурджанова, С. М. (2021). Влияние пандемии COVID-19 на поведенческие и психосоциальные факторы риска кардиоваскулярных заболеваний.
10. Зуфаров, П. С., Пулатова, Н. И., Мусаева, Л. Ж., & Авазова, Г. Н. (2023). *Содержание нерастворимого слизистого геля в желудочном соке у больных язвенной болезнью двенадцатиперстной кишки при применении стандартных схем квадритепии* (Doctoral dissertation, Ўзбекистон, Тошкент).
11. Karimov, M. M., Zufarov, P. S., Go'zal, N. S., Pulatova, N. I., & Aripdjanova, S. S. (2022). Ulinastatin in the conservative therapy of chronic pancreatitis. *Central Asian Journal of Medicine*, (3), 54-61.
12. Зуфаров, П. С., Якубов, А. В., & Салаева, Д. Т. (2009). СРАВНИТЕЛЬНАЯ ОЦЕНКА ЭФФЕКТИВНОСТИ ОМЕПРАЗОЛА И ПАНТОПРАЗОЛА ПРИ ЛЕЧЕНИИ ГАСТРОПАТИИ, ВЫЗВАННОЙ НЕСТЕРОИДНЫМИ ПРОТИВОВОСПАЛИТЕЛЬНЫМИ СРЕДСТВАМИ У БОЛЬНЫХ РЕВМАТОИДНЫМ АРТРИТОМ. *Лікарська справа*, (3/4), 44-49.



13. Karimov, M. M., Zufarov, P. S., Yakubov, A. V., & Pulatova, N. I. (2022). *Nospetsifik yarali kolitli bemorlar xususiyatlari* (Doctoral dissertation, Toshkent).
14. Karimov, M. M., Zufarov, P. S., Pulatova, D. B., Musaeva, L. J., & Aripdjanova, N. I. P. S. S. (2021). Functional dyspepsy: current aspects of diagnostics and treatment.
15. Саидова, Ш. А., Якубов, А. В., Зуфаров, П. С., Пулатова, Н. И., & Пулатова, Д. Б. (2024). ВЫБОР АНТАГОНИСТОВ МИНЕРАЛОКОРТИКОИДНЫХ РЕЦЕПТОРОВ ПРИ РАЗЛИЧНЫХ ПАТОЛОГИЯХ.
16. Акбарова, Д. С., Комолова, Ф. Д., Якубов, А. В., Зуфаров, П. С., Мусаева, Л. Ж., & Абдусаматова, Д. З. (2024). СРАВНИТЕЛЬНОЕ ИЗУЧЕНИЕ ЭФФЕКТИВНОСТИ И БЕЗОПАСНОСТИ ОТЕЧЕСТВЕННОГО ПРЕПАРАТА ЛЕВОФЛОКСАЦИНА РЕМОФЛОКС® НЕО У БОЛЬНЫХ С ВНЕБОЛЬНИЧНОЙ ПНЕВМОНИЕЙ.
17. Musayeva, L. J., Yakubov, A. V., Pulatova, N. I., Zufarov, P. S., Akbarova, D. S., & Abdusamatova, D. Z. (2023). WOMEN'S HEALTH AND DIFFICULTIES IN PREGNANCY. *Science and Society*, 1(1), 78-85.
18. Каримов, М. М., Зуфаров, П. С., Собирова, Г. Н., Каримова, Д. К., & Хайруллаева, С. С. (2023). Комбинированная терапия гастроэзофагеальной рефлюксной болезни при коморбидности с функциональной диспепсией. *Экспериментальная и клиническая гастроэнтерология*, (3), 41-45.
19. Karimov, M. M., Zufarov, P. S., & Sobirova, G. N. (2023). Evaluation of the Effectiveness of Eradication Therapy Based on Potassium-Competitive Acid Blockers in Patients with Helicobacter Pylori Associated Chronic Gastritis. *Journal of Coastal Life Medicine*, 11, 1481-1483.
20. Zufarov, P., Karimov, M., & Sayfiyeva, N. (2023). EVALUATION OF THE EFFECTIVENESS OF GASTRITIS IN THE TREATMENT OF FUNCTIONAL DYSPEPSIA. *Евразийский журнал медицинских и естественных наук*, 3(1 Part 1), 116-121.
21. Zufarov, P., Karimov, M., & Abdumajidova, N. (2023). CORRECTION OF PSYCHOEMOTIONAL STATUS IN GASTROESOPHAGEAL

E- Global Congress

Hosted online from Dubai, U. A. E., E - Conference.

Date: 30th January 2025

Website: <https://eglobalcongress.com/index.php/egc>

ISSN (E): 2836-3612

REFLUX DISEASE. *Евразийский журнал академических исследований*, 3(1 Part 3), 67-72.

22. Каримов, М. М., Рустамова, М. Т., Собирова, Г. Н., Зуфаров, П. С., & Хайруллаева, С. С. (2023). Оценка эффективности К-КБК вонопразана в комплексе эрадикационной терапии у больных с хроническими Нр-ассоциированными гастритами. *Экспериментальная и клиническая гастроэнтерология*, (12 (220)), 54-58.